Conclusions
NVAF
The OPTIMA‐4 trial offers an opportunity to assess the optimal dual antithrombotic regimen in ACS patients with concomitant NVAF after the implantation of new‐generation DES.Overview of the design of the OPtimal management of anTIthroMbotic Agents‐4 trial.
Xiaoxuan Gong, Rui Hua, and Jianling Bai contributed equally as co‐first authors.